Related Experiment Video
Updated: May 11, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Ipilimumab for patients with advanced mucosal melanoma
Michael A Postow1, Jason J Luke, Mark J Bluth
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. carvajar@mskcc.org
The Oncologist
|May 30, 2013
Summary
Ipilimumab showed limited efficacy in mucosal melanoma patients, with a low overall response rate and a median survival of 6.4 months. Further research is needed to define its role in treating this rare cancer subset.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Mucosal melanoma is a rare and aggressive subtype of melanoma.
- The efficacy of ipilimumab, an immune checkpoint inhibitor, in mucosal melanoma is not well-established.
Purpose of the Study:
- To evaluate the efficacy and safety of ipilimumab in patients with unresectable or metastatic mucosal melanoma.
- To assess treatment outcomes, toxicities, and immune responses in this patient population.
Main Methods:
- A multicenter, retrospective analysis of 33 patients with mucosal melanoma treated with ipilimumab.
- Data collected included clinical characteristics, treatments, toxicities, radiographic assessments, and mutational profiles.
- Humoral immunity against cancer-testis antigens was assessed using peripheral blood samples.
Main Results:
- Low overall response rates were observed: 1 complete response and 1 partial response (by both immune-related and WHO criteria) among 30 assessable patients.
- Median overall survival was 6.4 months.
- Immune-related adverse events included rash, diarrhea, thyroiditis, hepatitis, and hypophysitis.
Conclusions:
- Ipilimumab demonstrated limited efficacy in patients with mucosal melanoma, despite some durable responses observed.
- The overall response rate was low, suggesting a need for further investigation.
- Additional research is necessary to clarify the precise role of ipilimumab in managing mucosal melanoma.
Related Concept Videos
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.